---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-142014"
form_type: "8-K"
ticker: "CGEM"
cik: "0001789972"
company_name: "Cullinan Therapeutics, Inc."
filed_at: "2023-05-11T23:59:59+00:00"
generated_at: "2026-06-15T04:32:39.978472+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Cullinan Oncology Q1 net loss $58.1M; cash $503.5M; zipalertinib dose change

## Summary
- Net loss $58.1M for Q1 2023 vs $27.1M in Q4 2022; R&D expenses $52.1M including $25M upfront for CLN-418 license.
- Cash, equivalents, investments $503.5M as of March 31, 2023; runway into 2026.
- Zipalertinib pivotal study now enrolling at 100mg BID only; 150mg BID cohort discontinued per safety review.
- First clinical data for CLN-049 (EHA) and CLN-619 (ASCO) to be presented mid-2023.
- Licensed CLN-418 from Harbour Biomed for $25M upfront plus up to $563M in milestones and royalties.

## SEC filing metadata
- accession: 0001193125-23-142014
- form_type: 8-K
- ticker: CGEM
- cik: 0001789972
- company_name: Cullinan Therapeutics, Inc.
- filed_at: 2023-05-11T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1789972/000119312523142014/0001193125-23-142014-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1789972/000119312523142014/d470233d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-142014
- JSON: https://secwatch.observer/filing/0001193125-23-142014.json
- Plain text: https://secwatch.observer/filing/0001193125-23-142014.txt

## Key facts
- Earnings Releases
  Cullinan Therapeutics, Inc. reported financial results for the quarter ended March 31, 2023.
  - Period: the quarter ended March 31, 2023
  - Result: reported results
  source text: On May 11, 2023, Cullinan Oncology, Inc. announced its financial results for the quarter ended March 31, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1789972/000119312523142014/0001193125-23-142014-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.